Elanco Animal Health (ELAN) Receives $33.22 Consensus Target Price from Analysts

Elanco Animal Health (NASDAQ:ELAN) has received an average recommendation of “Hold” from the fourteen ratings firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and seven have given a buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $33.22.

ELAN has been the topic of several analyst reports. William Blair initiated coverage on shares of Elanco Animal Health in a report on Monday, February 11th. They issued a “market perform” rating and a $29.71 target price on the stock. UBS Group initiated coverage on shares of Elanco Animal Health in a report on Wednesday, January 23rd. They issued a “sell” rating and a $29.00 target price on the stock. Argus initiated coverage on shares of Elanco Animal Health in a report on Tuesday, January 15th. They issued a “buy” rating and a $37.00 target price on the stock. Credit Suisse Group reaffirmed a “hold” rating and issued a $33.00 target price on shares of Elanco Animal Health in a report on Friday, January 4th. Finally, Morgan Stanley initiated coverage on shares of Elanco Animal Health in a report on Wednesday, March 13th. They issued an “equal weight” rating and a $34.00 target price on the stock.

In related news, Director R David Hoover acquired 20,000 shares of Elanco Animal Health stock in a transaction that occurred on Wednesday, March 13th. The stock was purchased at an average price of $31.43 per share, for a total transaction of $628,600.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.



Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Morgan Stanley acquired a new stake in shares of Elanco Animal Health in the third quarter valued at about $314,448,000. Amundi Pioneer Asset Management Inc. lifted its stake in shares of Elanco Animal Health by 115,239.6% in the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 5,766,978 shares of the company’s stock valued at $181,833,000 after purchasing an additional 5,761,978 shares during the period. Vanguard Group Inc. acquired a new stake in shares of Elanco Animal Health in the third quarter valued at about $176,182,000. Vanguard Group Inc acquired a new stake in shares of Elanco Animal Health in the third quarter valued at about $176,182,000. Finally, FMR LLC lifted its stake in shares of Elanco Animal Health by 34.5% in the fourth quarter. FMR LLC now owns 4,415,172 shares of the company’s stock valued at $139,210,000 after purchasing an additional 1,131,504 shares during the period.

Elanco Animal Health stock traded down $0.43 during midday trading on Monday, hitting $32.14. 2,943,400 shares of the company’s stock were exchanged, compared to its average volume of 8,984,943. Elanco Animal Health has a 12-month low of $28.00 and a 12-month high of $37.61.

Elanco Animal Health (NASDAQ:ELAN) last issued its quarterly earnings data on Wednesday, February 6th. The company reported $0.29 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.26 by $0.03. The business had revenue of $799.30 million for the quarter, compared to analysts’ expectations of $804.07 million. During the same period in the previous year, the business posted $0.12 earnings per share. The company’s revenue for the quarter was up 6.0% on a year-over-year basis.

Elanco Animal Health Company Profile

There is no company description available for Elanco Animal Health Inc

Featured Article: What is a Derivative?

Analyst Recommendations for Elanco Animal Health (NASDAQ:ELAN)

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.